REHOVOT, Israel, October 11 /PRNewswire/ -- D-Pharm Ltd., a privately held biopharmaceutical company, announced today that the steering committee of the NeuroNE network & the Commission for the European Community has officially approved D-Pharm’s joining their European consortium, NeuroNE, for research into neurodegenerative disease. NeuroNE (www.euneurone.net) is Europe’s premiere research network for the creation of novel therapeutic approaches to neurodegenerative disease and neurotrauma and D-Pharm is honored to join this effort.
NeuroNE brings together top investigators from different backgrounds to work at all levels on neurodegenerative disease: post-genomic science, molecular and cell biology, animal models, therapeutic strategies and clinical studies. D-Pharm’s interests and expertise overlap considerably with NeuroNE’s goals and the company is expected to contribute to and benefit from contacts with the network at multiple levels. Indeed, the consortium’s project title: “Molecular Mechanisms of Neuronal Degeneration: from Cell Biology to the Clinic” is reflected in D-Pharm’s approach to in-house CNS drug discovery and development in acute stroke and neurodegeneration.
D-Pharm is developing a novel approach to neuroprotection based on selective modulation of calcium, zinc, copper and iron homeostasis in the vicinity of cell membranes. D-Pharm’s most advanced investigational drug, DP-b99, is poised to complete a Phase IIb clinical study in acute stroke patients and DP-460, in preclinical development, has demonstrated impressive anti-plaque effects as well as remarkable improvement of memory in transgenic mouse models for Alzheimer’s disease. Alex Kozak, D-Pharm’s CEO, noted that “Our technology addresses the novel therapeutic target of metal ion homeostasis within cell membranes and our drugs aim to treat the most devastating brain disorders. Access to the NeuroNE network and core facilities will enable us to realize the full potential of this pioneering technology and make our products available to the highly regarded researchers brought together in the network.”
D-Pharm (www.dpharm.com) is an integrated drug discovery and drug development organization with a rich and innovative pipeline of drug-candidates generated from its technology platform: Regulated Activation of Prodrugs (D-RAPTM); and its drug discovery platforms Membrane Active Chelators (MAC) and LipidoMimetix, bioactive lipids. D-Pharm focuses primarily on discovery, design and development of drugs for treatment of CNS disorders.
D-Pharm has two products in advanced Phase II, three early-stage Phase II programs and several products which can enter clinical development within 12 to 18 months. Results from the current Phase IIb study of D-Pharm’s investigational drug, DP-b99, in acute stroke patients are currently pending. DP-VPA is a Phase II candidate for epilepsy, with therapeutic potential in migraine prophylaxis and bipolar disorder. In addition, DP-460 is in preclinical development for Alzheimer’s disease and D-Pharm also has a number of earlier R&D stage cancer products.
For further information, please contact: Tami Horovitz D-Pharm Ltd. Tel: +972-8-9385100 Fax: +972-8-9300795 Email: thorovitz@dpharm.com
D-Pharm Ltd
CONTACT: For further information, please contact: Tami Horovitz, D-PharmLtd. Tel: +972-8-9385100, Fax: +972-8-9300795, Email: thorovitz@dpharm.com
